Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
54,253,774
-
Share change
-
+540,292
-
Total reported value
-
$4,048,407,950
-
Put/Call ratio
-
24%
-
Price per share
-
$74.61
-
Number of holders
-
297
-
Value change
-
+$51,089,019
-
Number of buys
-
160
-
Number of sells
-
150
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2025
As of 30 Jun 2025,
HAEMONETICS CORP - Common Stock (HAE) was held by
297 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
54,253,774 shares.
The largest 10 holders included
BlackRock, Inc., VANGUARD GROUP INC, NEUBERGER BERMAN GROUP LLC, WELLINGTON MANAGEMENT GROUP LLP, STATE STREET CORP, River Road Asset Management, LLC, T. Rowe Price Investment Management, Inc., ROYCE & ASSOCIATES LP, GEODE CAPITAL MANAGEMENT, LLC, and Capital Research Global Investors.
This page lists
297
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.